Please assess the completion status of the following clinical trial:

Trial Title: Urinary Track Infection Prevention After Urogynecological Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who undergo major pelvic organ prolapse surgery that are diagnosed with POUR via failed retrograde void trial and require an indwelling Foley catheter upon hospital discharge.~Exclusion Criteria:~* Unwillingness to participate in the study~* Inability to understand English~* Pregnant women~* Patient personal history of nephrolithiasis, urogenital anomaly, neurogenic bladder, chronic renal insufficiency (GFR \<60 ml/min/1.73 m² or serum creatinine level \>1.03 for \>3months), sarcoidosis, and severe hepatic insufficiency~* Currently (prior 3 months) undergoing medical management for recurrent UTI or interstitial cystitis~* Active urinary tract infection~* Patient history of taking Warfarin (Coumadin)~* Intraoperative bladder injury or cystotomy~* Physical or mental impairment that would affect the subject's ability to take medications daily or fill out questionnaires~* Reported allergy to any of the ingredients in the cranberry, MH, or placebo pill

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Methenamine Hippurate with Cranberry (Type: EXPERIMENTAL): Subjects will be instructed to take Methenamine Hippurate 1 g tablet ( 1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.
- Placebo with Cranberry (Type: PLACEBO_COMPARATOR): Subjects will be instructed to take Placebo tablet (1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.~Cranberry capsules were incorporated into the standard practice of Cincinnati Urogynecology Associates, TriHealth Inc in mid-March 2016.

Based on this trial design, predict the completion outcome and termination type (if applicable).